

Company highlights

- Founded in 1913
- Headquartered in Budapest, Hungary
- Member of the Servier Group

Turnover data


- 693 million EUR (2023/24) business year, +10%
- licenced-in products account for 25% of total sales

Activities

- Dedicated to market branded generics (hard-to-make & commodity), biosimilars, food supplements, medical devices
- Own API and FDF development & manufacturing, complemented with in-licensed products (oral solids, oral liquids, injections, topical forms)
- 3 manufacturing sites in Hungary (FDF and API), holding several GMP certificates (EU, USA, Japan, Brazil, EAEU, South-Korea)
- Egis Pharma Services: CDMO for small molecule drugs and intermediates

Therapy areas and product types:

- Cardiometabolic, CNS: core therapy areas
- Consumer healthcare: focus on allergy, cough, wound care
CHC accounts for 22% of total turnover
- Oncology, women's health, gastroenterology, rheumatology, dermatology: focus in selected countries




Presence & Geographical Focus



Presence

- Products available in **100** countries
- Besides Hungary **17** subsidiaries and representative offices:
 - **CEE:** PL, CZ, SK, RO, BG, LT, LV
 - **EAEU & CIS:** RU, BY, KZ, AM, UA, AZ, GE, MD, UZ
 - VN



 Presence through our subsidiaries or representative offices

 Sales through our partners

Sales – share by territory

- Largest markets: **HU, PL, RU**

